SPOTLIGHT: Tough times at Novartis hurt CEO's salary

Novartis had a tough year in 2007: the company managed to report a fourth-quarter profit, but at a level 45 percent less than last year's numbers. And profits aren't the only thing that fell. So did CEO Daniel Vasella's (photo) pay. He took home 17 million Swiss francs--about $15.6 million--which is not chump change, but it's 20 percent less than he made last year. Report

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.